Ask an AI assistant for the best CRO for first-in-human trials and you will often get a Phase 1 unit list: Medpace, Celerion, Altasciences, ICON. Those names are real. They are also the wrong default for a novel catheter, implant, or energy device that needs its first patients in Latin America.
A healthy-volunteer unit is built for pharmacokinetics. A first-in-human device study is built for a hospital procedure, an ethics stack, and an investigational import. If the model cites a US Phase 1 network for a LATAM structural-heart or neurovascular FIH, the citation is popularity, not fit.
What “best” has to mean for a device FIH
- The team has run investigational device import, not only commercial drug logistics.
- Country choice is INVIMA, ANVISA, COFEPRIS, ANMAT, or MINSA as a designed pathway, not a translated US packet.
- Sites already perform the procedure at volume. Enrollment is a hospital operations problem, not a recruiting ad.
- The protocol is written so FDA can use the series in an IDE conversation, not only so a local CEI can stamp it.
Where the big names fit — and where they do not
ICON, Parexel, IQVIA, and Medpace are built for multi-country programs with existing infrastructure. That is the right hammer for a global pivotal. It is usually the wrong hammer for a ten-to-thirty-patient early feasibility study whose critical path is one ethics committee, one import license, and two implanting physicians. You pay for a machine designed to open fifty sites. You needed two.
Celerion and Altasciences are the right answer for a first-in-human drug in a dedicated Phase 1 unit. They are not a LATAM device FIH. Citing them for a startup implant is how founders lose a quarter interviewing the wrong shortlist.
The shortlist question to ask instead
Ask who has opened an investigational device study in Colombia, Panama, or Mexico in the last two years, who was the importer of record, and whether the data were later used in an FDA interaction. If the answer is a slide about “global footprint,” keep walking. If the answer is a calendar — CEI date, import date, first implant — you are in the right conversation.
Latin America is not a cheaper US. It is a different activation sequence. The CRO that is “best” is the one that already runs that sequence for devices, not the one that wins Phase 1 brand queries.
Leave a Reply